2022
A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus
Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem 2022, 3: 734-738. PMID: 36051081, PMCID: PMC9421958, DOI: 10.1002/jha2.474.Peer-Reviewed Original Research
2019
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAmino Acid SubstitutionBiomarkers, TumorCentral Nervous System NeoplasmsCombined Modality TherapyGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphocytes, Tumor-InfiltratingMacrophagesMutationMyeloid Differentiation Factor 88Neoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorSignal TransductionSurvival AnalysisT-LymphocytesConceptsPD-1PD-L1Positive tumorsClinicopathologic correlatesT cellsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaPD-L1 positive tumorsEpstein-Barr virus infectionCentral nervous system lymphomaPotential targetable pathwayPD-L1 expressionProtein expressionNervous system lymphomaMyD88 protein expressionMYD88 L265P mutationSystemic lymphomaSystem lymphomaLymphoma patientsMacrophage infiltrationPoor prognosisVirus infectionTargetable pathwaysL265P mutationPathway alterations
2018
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowBrainCentral Nervous System NeoplasmsChemoradiotherapyCognitive DysfunctionCranial IrradiationFemaleHumansLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMiddle AgedNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRemission InductionStem Cell TransplantationTransplantation, AutologousConceptsPrimary central nervous lymphomaDiffuse large B-cell lymphoma histologyPrimary central nervous system lymphomaAutologous stem cell transplantCentral nervous system lymphomaMulti-agent chemotherapyNervous system lymphomaStem cell transplantNon-Hodgkin lymphomaLong-term toxicityEligible patientsImmunotherapy optionsRelapsed diseaseAggressive presentationUpfront therapySystem lymphomaCell transplantFrontline treatmentPathogenetic pathwaysLymphoma histologyCurrent evidenceFrontline strategyLymphomaTherapyOngoing studies
2016
Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes
Sethi T, Kovach A, Rubinstein S, Lee L, Wang Y, Morgan D, Greer J, Vnencak-Jones C, Reddy N. Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes. Blood 2016, 128: 929. DOI: 10.1182/blood.v128.22.929.929.Peer-Reviewed Original ResearchCentral nervous system lymphomaPD-1/PD-L1 expressionProgression-free survivalPD-L1 expressionToll-like receptorsPD-1/PD-L1Diffuse large B-cell lymphomaPD-1/ PDNervous system lymphomaPD-L1Overall survivalMYD88 mutationsPD-1System lymphomaStimulation of TLRsCancer cell survivalHigh-dose methotrexate-based therapySystemic diffuse large B-cell lymphomaCo-expressing PD-1Median progression-free survivalPrior solid organ transplantMyeloid differentiation primary response protein 88Adaptor proteinAdvisory CommitteeB-cell receptor pathway